Callan Family Office LLC Increases Stake in Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• Callan Family Office LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 50.2%, owning 29,877 shares valued at approximately $854,000 by the end of the recent quarter.
• Shares of Fresenius Medical Care opened at $26.78, with a market capitalization of $15.71 billion and a price-to-earnings ratio of 21.95.
• Recent earnings showed the company reported $0.52 EPS for the quarter, exceeding analyst estimates of $0.50, while revenue reached $5.54 billion.

Callan Family Office LLC raised its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 50.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,877 shares of the company's stock after purchasing an additional 9,979 shares during the period. Callan Family Office LLC's holdings in Fresenius Medical Care AG & Co. KGaA were worth $854,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FMS. GAMMA Investing LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 34.0% in the 1st quarter. GAMMA Investing LLC now owns 9,603 shares of the company's stock valued at $239,000 after purchasing an additional 2,439 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 3,654.9% in the 1st quarter. Fifth Third Bancorp now owns 7,660 shares of the company's stock valued at $191,000 after purchasing an additional 7,456 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 4.9% in the 1st quarter. QRG Capital Management Inc. now owns 71,293 shares of the company's stock valued at $1,775,000 after purchasing an additional 3,320 shares in the last quarter. TrueMark Investments LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at $675,000. Finally, Spire Wealth Management purchased a new position in Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at $27,000. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.4%

Shares of NYSE:FMS opened at $26.78 on Monday. The business has a 50-day moving average price of $25.33 and a 200 day moving average price of $26.24. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $15.71 billion, a price-to-earnings ratio of 21.95, a PEG ratio of 0.61 and a beta of 0.92. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.94 and a 12-month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The firm had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $5 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%. Sell-side analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. Finally, UBS Group reiterated a "sell" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of "Hold" and a consensus price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.